首页> 外文期刊>American Journal of Transplantation >Fibronectin-4β1 Interactions in Hepatic Cold Ischemia and Reperfusion Injury: Regulation of MMP-9 and MT1-MMP via the p38 MAPK Pathway
【24h】

Fibronectin-4β1 Interactions in Hepatic Cold Ischemia and Reperfusion Injury: Regulation of MMP-9 and MT1-MMP via the p38 MAPK Pathway

机译:纤连蛋白-4β1在肝冷缺血和再灌注损伤中的相互作用:通过p38 MAPK途径调节MMP-9和MT1-MMP

获取原文
获取原文并翻译 | 示例
           

摘要

Liver ischemia-reperfusion injury (IRI) remains a challenging problem in clinical settings. The expression of fibronectin (FN) by endothelial cells is a prominent feature of the hepatic response to injury. Here we investigate the effects of the connecting segment-1 (CS-1) peptide therapy, which blocks FN-4β1 integrin leukocyte interactions, in a well-established model of 24-h cold liver IRI. CS-1 peptides significantly inhibited leukocyte recruitment and local release of proinflammatory mediators (COX-2, iNOS and TNF-), ameliorating liver IRI and improving recipient survival rate. CS1 therapy inhibited the phosphorylation of p38 MAPK, a kinase linked to inflammatory processes. Moreover, in addition to downregulating the expression of matrix metalloproteinase-9 (MMP-9) in hepatic IRI, CS-1 peptide therapy depressed the expression of membrane type 1-matrix metalloproteinase (MT1-MMP/MMP-14) by macrophages, a membrane-tethered MMP important for focal matrix proteolysis. Inhibition of p38 MAPK activity, with its pharmacological antagonist SB203580, downregulated MMP-9 and MT1-MMP/MMP-14 expressions by FN-stimulated macrophages, suggesting that p38 MAPK kinase pathway controls FN-mediated inductions of MMP-9 and MT1-MMP/MMP-14. Hence, this study provides new insights on the role of FN in liver injury, which can potentially be applied to the development of new pharmacological strategies for the successful protection against hepatic IRI.
机译:肝脏缺血再灌注损伤(IRI)在临床环境中仍然是一个具有挑战性的问题。内皮细胞表达纤连蛋白(FN)是肝脏对损伤的反应的重要特征。在这里,我们研究了在成熟的24小时冷肝IRI模型中阻断FN-4β1整合素白细胞相互作用的连接区段1(CS-1)肽疗法的作用。 CS-1肽可显着抑制白细胞募集和促炎性介质(COX-2,iNOS和TNF-)的局部释放,改善肝脏IRI并提高受体存活率。 CS1疗法抑制了与炎症过程相关的激酶p38 MAPK的磷酸化。此外,CS-1肽疗法除了下调肝IRI中基质金属蛋白酶9(MMP-9)的表达外,还抑制了巨噬细胞膜型1基质金属蛋白酶(MT1-MMP / MMP-14)的表达。膜连接的MMP对局灶性基质蛋白水解很重要。用其药理拮抗剂SB203580抑制p38 MAPK活性,通过FN刺激的巨噬细胞下调MMP-9和MT1-MMP / MMP-14的表达,这表明p38 MAPK激酶途径控制FN介导的MMP-9和MT1-MMP的诱导/ MMP-14。因此,本研究提供了关于FN在肝损伤中的作用的新见解,可将其潜在地应用于开发新药理学策略,以成功保护肝脏IRI。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号